A Phase1 b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
GlaxoSmithKline
Summary
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or met…
Interventions
- BiologicalRisvutatug Rezetecan
Risvutatug Rezetecan will be administered
- DrugDrug 1
Drug 1 will be administered
- DrugDrug 2
Drug 2 will be administered
- DrugDrug 3
Drug 3 will be administered
- DrugDrug 4
Drug 4 will be administered
Locations (85)
- GSK Investigational SiteLos Alamitos, California
- GSK Investigational SiteLos Angeles, California
- GSK Investigational SiteSanta Monica, California
- GSK Investigational SiteWhittier, California
- GSK Investigational SiteAurora, Colorado
- GSK Investigational SiteNew York, New York